This directory serves as a resource listing of active biotech that develop therapeutics, diagnostics and/or medtech. The companies listed in this directory are not representative of the companies that are active members of the Biotech and Money community.
Add / Amend your company listing for free
(only active biotech ie. therapeutic, diagnostic and medtech companies are eligible for listing)
Poland
Mabion is focused on development of humanized monoclonal antibodies (mAbs) technology, the newest generation of biotechnological drugs. Mabion is currently testing its product for use in treating in breast cancer and then will focus on lymphoma therapy.
Selvita is a Polish, biotechnology company engaged in the discovery and development of breakthrough medicines to treat CNS, oncology and autoimmune disorders, as well as provision of drug discovery services.
It was established and 2007 and currently employs 150 scientists, including over 50 PhDs. Selvita has currently several projects at early or late discovery stage and is expected to move its first candidates to the clinic in 2014.
The most advanced programs at Selvita are SEL24, a pre-clinical Pim kinase inhibitor, with multiple indications in hematopoietic tumors, SEL120, focused on first-in-class small molecule inhibitor of cyclin dependent kinase: CDK8, and SEL128, aimed at development of inhibitors of several novel kinases in cancer, involved with signal transduction and cancer metabolism.
Other innovative projects currently in development include SEL141, an early stage discovery program of a series of DYRK1A kinase inhibitors with therapeutic potential in the treatment of tauopathies, including Alzheimer's disease and Down syndrome, and SEL212, NALP3 inflammasome modulators for the treatment of autoinflammatory and autoimmune disorders
It was established and 2007 and currently employs 150 scientists, including over 50 PhDs. Selvita has currently several projects at early or late discovery stage and is expected to move its first candidates to the clinic in 2014.
The most advanced programs at Selvita are SEL24, a pre-clinical Pim kinase inhibitor, with multiple indications in hematopoietic tumors, SEL120, focused on first-in-class small molecule inhibitor of cyclin dependent kinase: CDK8, and SEL128, aimed at development of inhibitors of several novel kinases in cancer, involved with signal transduction and cancer metabolism.
Other innovative projects currently in development include SEL141, an early stage discovery program of a series of DYRK1A kinase inhibitors with therapeutic potential in the treatment of tauopathies, including Alzheimer's disease and Down syndrome, and SEL212, NALP3 inflammasome modulators for the treatment of autoinflammatory and autoimmune disorders